Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182‐ICON5
暂无分享,去创建一个
[1] Robert S Mannel,et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Bookman. Developmental chemotherapy and management of recurrent ovarian cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] I. Tannock,et al. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.
[4] H. V. van Houwelingen,et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Piccart,et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.
[6] F M Muggia,et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Ozols,et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.
[9] E. Eisenhauer,et al. Carboplatin versus cisplatin , 1993 .